Who is sponsoring NCT02201355?

NCT02201355 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT02201355?

Interventions in NCT02201355: Intensity Modulated Radiotherapy.

What condition does NCT02201355 study?

NCT02201355 studies Squamous Cell Carcinoma of the Head and Neck T1/2N0-2.

Is NCT02201355 still recruiting?

NCT02201355 is currently terminated. Last updated 2 February 2021.

Last reviewed 2021-02-02 · How we verify

NCT02201355

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck

Terminated Phase 1 Last updated 2 February 2021

What this trial tests

Phase 1 trial testing Intensity Modulated Radiotherapy in Squamous Cell Carcinoma of the Head and Neck T1/2N0-2 in 8 participants. Terminated before completion.

Timeline

18 September 2014

Primary endpoint
23 January 2018

15 May 2020

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	18 September 2014
Primary completion	23 January 2018
Estimated completion	15 May 2020
Sites	1 location across United States

Drugs / interventions tested

Intensity Modulated Radiotherapy

Conditions studied

Squamous Cell Carcinoma of the Head and Neck T1/2N0-2 — all drugs for Squamous Cell Carcinoma of the Head and Neck T1/2N0-2 →

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 18 to 99, any sex, with Squamous Cell Carcinoma of the Head and Neck T1/2N0-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objectives: To determine whether patients with T1/2N0-2 Squamous Cell Carcinoma of the oropharynx, hypopharynx or larynx can tolerate treatment with cisplatin chemoradiation in three weeks using reduced volume IMRT Secondary Objectives: To describe the adverse events associated with hypofractionated, reduced volume cisplatin chemoradiation. To estimate response rates and progression-free survival rates of hypofractionated, reduced volume cisplatin chemoradiation. To determine HRQOL following hypofractionated, reduced volume cisplatin chemoradiation. If patients can safely be treated in three weeks rather than six weeks, such a schedule would provide a much more convenient alternative for patients and result in a significant reduction in the health care resources currently expended on cure of these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intensity Modulated Radiotherapy

Trials testing the same drug.

NCT06546267 — Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART) · recruiting
NCT02753790 — Whole Brain Radiation Using IMRT for Patients With Brain Metastases · NA · completed

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02201355 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 2 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02201355.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing